Abstract
Vaccines can provide protection against infection or reduce disease progression and severity. Vaccine efficacy (VE) is typically evaluated independently for different outcomes, but this can cause biased estimates of VE. We propose a new analytical framework based on a model of disease progression for VE estimation for infections with multiple possible outcomes of infection: Joint analysis of multiple outcomes in vaccine efficacy trials (JAMOVET). JAMOVET is a Bayesian hierarchical regression model that controls for biases and can evaluate covariates for VE, the risk of infection, and the probability of progression. We applied JAMOVET to simulated data, and data from COV002 (NCT04400838), a phase 2/3 trial of ChAdOx1 nCoV-19 (AZD1222) vaccine. Simulations showed that biases are corrected by explicitly modelling disease progression and imperfect test characteristics. JAMOVET estimated ChAdOx1 nCoV-19 VE against infection (VEin) at 47% (95% CI 36-56) and progression to symptoms (VEpr) at 48% (95% CI 32-61). This implies a VE against symptomatic infection of 72% (95% CI 63-80), consistent with published trial estimates. VEin decreased with age while VEpr increased with age. JAMOVET is a powerful tool for evaluating diseases with multiple dependent outcomes and can be used to adjust for biases and identify predictors of key outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04400838
Funding Statement
This work was supported by payments made to the Imperial College London, MRC Centre for Global Infectious Disease Analysis (grant number MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union. This work was also supported by the MRC Doctoral Training Partnership (to LRW) and the Imperial College President's Scholarship (to LRW).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The COV002 trial was given ethical approval by the South Central Berkshire Research Ethics Committee (reference 20/SC/0179; conditional approval April 8, full approval April 19, 2020).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Anonymised participant data is available upon requests directed to the Oxford Vaccine Group*. Proposals will be reviewed and approved by the sponsor, investigator, and collaborators on the basis of scientific merit. After approval of a proposal, data can be shared through a secure online platform after signing a data access agreement. All data will be made available for a minimum of 5 years from the end of the trial. *Prof Andrew J Pollard, Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford OX3 7LE, UK andrew.pollard@paediatrics. ox.ac.uk.
